NEUWIRTHOVÁ, Jana, Zdeněk MECHL, Rom KOSTŘICA and Pavel SMILEK. Panitumumab. Remedia. Praha, 2008, 18.ročník, 1/2008, p. 67-69. ISSN 0862-8947.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Panitumumab
Name in Czech Panitumumab
Name (in English) Panitumumab
Authors NEUWIRTHOVÁ, Jana, Zdeněk MECHL, Rom KOSTŘICA and Pavel SMILEK.
Edition Remedia, Praha, 2008, 0862-8947.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Organization unit Faculty of Medicine
Keywords in English panitumumab ABX-EGF monoclonal antibody targeted therapy EGFR colorectal cancer head and neck cancer
Tags ABX-EGF, Colorectal cancer, EGFR, head and neck cancer, monoclonal antibody, panitumumab, targeted therapy
Changed by Changed by: MUDr. Jana Neuwirthová, Ph.D., učo 22135. Changed: 18/2/2010 20:09.
Abstract
Panitumumab je plně humanizovaná monoklonální protilátka, blokující receptor pro epidermální růstový faktor, který je exprimován na mnoha typech nádorů. Tento přípravek patří do tzv. cílené léčby. Současně s hledáním nejvhodnějších onkologických indikací se pozornost zaměřuje i na prediktivní markery této léčby.
Abstract (in English)
Panitumumab is fully humanized monoclonal antibody directed against the epidermal growth factor receptor, expressed in variety of tumors. It is a targeted therapy. Attention is being paid to the identification of oncological indications and predictive markers of this therapy.
PrintDisplayed: 9/8/2024 01:20